CEL-SCI Home Page
preload preload

CEL-SCI CEO on Fox

Press Releases

Feb. 2018 CEO Presentation

Press Releases

September 28, 2018
NEW STORY CEL-SCI Announces Warrants to Expire on October 11, 2018

September 14, 2018
NEW STORY CEL-SCI Receives $5.4 Million from Warrant Exercises

September 5, 2018
NEW STORY NIH Selects CEL-SCI's LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program

August 21, 2018
NEW STORY CEL-SCI Corporation Releases Letter to Shareholders

August 17, 2018
NEW STORY CEL-SCI Announces that the NYSE American Approves Plan

August 15, 2018
NEW STORY CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

August 14, 2018
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results

July 13, 2018
NEW STORY CEL-SCI Reports on NYSE American Noncompliance Notice and Compliance Plan

July 9, 2018
NEW STORY CEL-SCI Corporation Issues Letter to Shareholers

July 2, 2018
NEW STORY CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering

June 28, 2018
NEW STORY CEL-SCI Announces $5 Million Registered Direct Offering

June 27, 2018
NEW STORY CEL-SCI Receives $2.1 Million from Warrant Exercises

June 27, 2018
NEW STORY CEL-SCI Wins Breach of Contract Ruling Against Clinical Research Organization inVentiv, Now Known as Syneos Health

June 11, 2018
CEL-SCI Corporation Issues Letter to Shareholders

June 8, 2018
U.S. Patent Office Allows New CEL-SCI Patents for LEAPS Vaccine Platform Technology

May 30, 2018
CEL-SCI Announces Reminder of Warrant Exercise Price

 

ADDITIONAL RELEASES
View All Corporate Press Releases


 

THE CEL-SCI STORY